Promising Formulation of New Sarclisa Subcutaneous Treatment Meets Co-Primary Endpoints in IRAKLIA Phase 3
Formulation Results from the IRAKLIA Phase 3 Study Demonstrate Promise for Subcutaneous Sarclisa in Multiple Myeloma The Formulation IRAKLIA Phase 3 study has presented encouraging results for the investigational subcutaneous…
Biologics License Grifols Submits Application to U.S. FDA for Innovative Fibrinogen Solution
Biologics License Grifols Advances Fibrinogen Solution with U.S. FDA Submission Biologics License Grifols a global healthcare company and leading manufacturer of plasma-derived medicines, has announced the submission of a Biologics…
Ailux Biologics Triumphantly UCB Collaborates with XtalPi Division to Revolutionize AI-Powered Biologics
Ailux Biologics UCB\u2019s Strategic Collaboration with Ailux Biologics Ailux Biologics UCB, a leading global biopharmaceutical company, and XtalPi, an industry pioneer in AI-powered drug discovery, have announced a landmark license…
Poseida Therapeutics Roche Acquires Majority Shares in Tender Offer
Roche Acquires Poseida Therapeutics: $9.00 per Share Tender Offer Completed Poseida Therapeutics Roche a global leader in the pharmaceutical and diagnostics industries, has announced the successful completion of its tender…
Breakthrough Cardiometabolic Disease Treatments Valo Health and Novo Nordisk Expand Collaboration
Novo Nordisk and Valo Health Expand Partnership to Accelerate Cardiometabolic Disease Treatment Discovery Novo Nordisk A/S and Valo Health have announced a significant expansion of their collaboration aimed at discovering…
Groundbreaking Glucocorticoid Treatment in Congenital Adrenal Hyperplasia Neurocrine Biosciences Publishes Study $10 Million
Impact of High-Dose Glucocorticoid Therapy on Long-Term Health Neurocrine Biosciences has announced the publication of a comprehensive narrative review exploring the complexities of traditional glucocorticoid (GC) treatment for classic congenital…
Announces Breakthrough G-Rex® Grant: $125,000 Awarded to Seattle Children’s Therapeutics
Children’s Therapeutics ScaleReady Partners with Industry Leaders to Support Seattle Announces Children’s Therapeutics ScaleReady, in partnership with Wilson Wolf Manufacturing and Bio-Techne Corporation, has announced that Seattle Children’s Therapeutics, a…
Malaria WHO Approves Breakthrough Test for Safer P. vivax Treatment
The Role of G6PD Testing in Malaria Treatment On December 18, 2024, the World Health Organization (WHO) achieved a groundbreaking milestone by prequalifying the first diagnostic test for glucose-6-phosphate dehydrogenase…
Bio-Techne Scores Major Victory in 2 Reverse Engineering Claim Against Miltenyi Biotec
Bio-Techne Prevails in Second Case Against Miltenyi Biotec for Reverse Engineering of Antibodies Corporation announced today that it has successfully won another legal claim against Miltenyi Biotec B.V. & Co.…
Biopharma A Cautiously Optimistic Outlook for 2025
A Cautiously Optimistic Outlook for Biopharma in 2025 The biopharma sector is poised for a cautious but optimistic rebound in 2025, driven by renewed investment, the growing influence of artificial…
Alzheimer’s Disease Breakthrough Unveiling the Mechanism Behind Lecanemab’s Role in Slowing Progression 2025
New Insights into Lecanemab’s Role in Slowing Alzheimer’s Disease Progression A groundbreaking study led by Professor Kenjiro Ono of the Institute of Medical, Pharmaceutical, and Health Sciences at Kanazawa University,…
Osteosarcoma Breakthrough GSK’s B7-H3 ADC GSK’227 Gains FDA Breakthrough Designation
GSK Receives FDA Breakthrough Therapy Designation for GSK5764227 in Osteosarcoma Treatment GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for…